These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 26114655)

  • 1. Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse.
    Song LK; Ma KL; Yuan YH; Mu Z; Song XY; Niu F; Han N; Chen NH
    PLoS One; 2015; 10(6):e0131281. PubMed ID: 26114655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased expression of serum- and glucocorticoid-inducible kinase 1 (SGK1) promotes alpha-synuclein increase related with down-regulation of dopaminergic cell in the Substantia Nigra of chronic MPTP-induced Parkinsonism mice and in SH-SY5Y cells.
    Yeo S; Sung B; Hong YM; van den Noort M; Bosch P; Lee SH; Song J; Park SK; Lim S
    Gene; 2018 Jun; 661():189-195. PubMed ID: 29604467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression.
    Bourdenx M; Dovero S; Engeln M; Bido S; Bastide MF; Dutheil N; Vollenweider I; Baud L; Piron C; Grouthier V; Boraud T; Porras G; Li Q; Baekelandt V; Scheller D; Michel A; Fernagut PO; Georges F; Courtine G; Bezard E; Dehay B
    Acta Neuropathol Commun; 2015 Jul; 3():46. PubMed ID: 26205255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
    Dong Z; Ferger B; Feldon J; Büeler H
    J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Geraniol attenuates α-synuclein expression and neuromuscular impairment through increase dopamine content in MPTP intoxicated mice by dose dependent manner.
    Rekha KR; Selvakumar GP; Santha K; Inmozhi Sivakamasundari R
    Biochem Biophys Res Commun; 2013 Nov; 440(4):664-70. PubMed ID: 24103762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.
    Decressac M; Mattsson B; Björklund A
    Exp Neurol; 2012 May; 235(1):306-15. PubMed ID: 22394547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system.
    Gombash SE; Manfredsson FP; Kemp CJ; Kuhn NC; Fleming SM; Egan AE; Grant LM; Ciucci MR; MacKeigan JP; Sortwell CE
    PLoS One; 2013; 8(11):e81426. PubMed ID: 24312298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
    Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
    Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
    Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
    Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
    Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A
    Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-synuclein overexpression model.
    Mochizuki H; Yamada M; Mizuno Y
    J Neural Transm Suppl; 2006; (70):281-4. PubMed ID: 17017543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson's disease and does not lead to a sustainable increase of brain-derived neurotrophic factor.
    Komnig D; Dagli TC; Habib P; Zeyen T; Schulz JB; Falkenburger BH
    J Neurochem; 2018 Dec; 147(5):678-691. PubMed ID: 30152864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-related biphasic effect of the Parkinson's disease neurotoxin MPTP, on the spread, accumulation, and toxicity of α-synuclein.
    Merghani MM; Ardah MT; Al Shamsi M; Kitada T; Haque ME
    Neurotoxicology; 2021 May; 84():41-52. PubMed ID: 33549656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allelic difference in Mhc2ta confers altered microglial activation and susceptibility to α-synuclein-induced dopaminergic neurodegeneration.
    Jimenez-Ferrer I; Jewett M; Tontanahal A; Romero-Ramos M; Swanberg M
    Neurobiol Dis; 2017 Oct; 106():279-290. PubMed ID: 28736195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of TorsinA as a target for Parkinson disease therapy in mouse models.
    Li X; Lee J; Parsons D; Janaurajs K; Standaert DG
    PLoS One; 2012; 7(11):e50063. PubMed ID: 23185535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
    Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
    Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons.
    Kowall NW; Hantraye P; Brouillet E; Beal MF; McKee AC; Ferrante RJ
    Neuroreport; 2000 Jan; 11(1):211-3. PubMed ID: 10683860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.